The GLP-2R variant D470N (32% allele frequency) increases cAMP signaling and is associated with increased obesity, T2D, BMI, and blood pressure in 500,000 UK Biobank participants.
32% carry the variantNearly one-third of the UK population carries D470N, a GLP-2R gain-of-function variant linked to increased metabolic risk
What the researchers found
D470N (32% frequency) increases GLP-2R cAMP via reduced β-arrestin/internalization and is associated with increased obesity, T2D, BMI, body fat, HbA1c, and blood pressure in ~500K UK Biobank participants. LoF variants associated with decreased obesity/fat.
Why it matters
GLP-2R drugs are being developed for intestinal diseases. This study reveals unexpected metabolic risks of GLP-2R activation that must be monitored in drug development.
How the study worked
In vitro pharmacological characterization of 30 GLP-2R missense variants (cAMP, β-arrestin 2), identification of 34 predicted LoF variants, and genetic association testing in ~500,000 UK Biobank participants.
What this study cannot tell us
Genetic associations don't prove causation. Tissue-specific GLP-2R effects may differ (gut beneficial, systemic harmful). UK Biobank population may not represent all ethnicities.
How to read the evidence
Robust pharmacogenomic study combining functional characterization with ~500K participant genetic association. Strong evidence for GLP-2R metabolic effects.
When this study was published
Published in 2025.
The bigger picture
While GLP-1R agonism treats obesity, GLP-2R activation may worsen it — a crucial distinction for peptide drug developers targeting the incretin family.
Questions still open
- Should GLP-2R drug development monitor metabolic outcomes carefully?
- Could biased GLP-2R agonists that avoid cAMP hyperactivation be safer?
- Is the D470N variant relevant for GLP-2R drug response prediction?
Common questions
What is GLP-2 and how is it different from GLP-1?
Does this affect people taking GLP-1 drugs?
Read the original research
Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.
Metabolism: clinical and experimental, 177, 156489
Citation
Gerlach, Peter A; Gadgaard, Sarina; Madsen, Jakob S; Lindquist, Peter; Lorente, Javier Sanchez; Faas, Felix; Gabe, Maria B N; Rosenkilde, Mette M; Hauser, Alexander S. (2026). Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.. Metabolism: clinical and experimental, 177, 156489. https://doi.org/10.1016/j.metabol.2025.156489